Market Cap 410.77M
Revenue (ttm) 0.00
Net Income (ttm) -161.65M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 4,007,700
Avg Vol 1,826,650
Day's Range N/A - N/A
Shares Out 283.29M
Stochastic %K 83%
Beta 1.12
Analysts Strong Sell
Price Target $4.57

Latest News on ERAS

Erasca to Present at Upcoming Investor Conferences in June

May 29, 2025, 8:00 AM EDT - 4 days ago

Erasca to Present at Upcoming Investor Conferences in June


Erasca, Inc.: Carving A Different Niche In RAS Signaling

Apr 25, 2025, 11:33 AM EDT - 5 weeks ago

Erasca, Inc.: Carving A Different Niche In RAS Signaling


Erasca's Naporafenib Is Shaping Up Nicely For NRASm Melanoma

Jan 27, 2025, 12:09 AM EST - 4 months ago

Erasca's Naporafenib Is Shaping Up Nicely For NRASm Melanoma


Erasca to Present at Upcoming Investor Conferences

Nov 5, 2024, 8:00 AM EST - 7 months ago

Erasca to Present at Upcoming Investor Conferences


Erasca: Potential Strong Upside Ahead

Feb 8, 2023, 11:21 AM EST - 2 years ago

Erasca: Potential Strong Upside Ahead


Erasca to Present at the Guggenheim Oncology Conference 2023

Feb 1, 2023, 8:00 AM EST - 2 years ago

Erasca to Present at the Guggenheim Oncology Conference 2023